1. Home
  2. BGI vs ABP Comparison

BGI vs ABP Comparison

Compare BGI & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birks Group Inc.

BGI

Birks Group Inc.

HOLD

Current Price

$1.04

Market Cap

22.7M

Sector

N/A

ML Signal

HOLD

ABP

Abpro Holdings Inc

HOLD

Current Price

$5.87

Market Cap

18.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGI
ABP
Founded
1879
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.7M
18.8M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
BGI
ABP
Price
$1.04
$5.87
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
28.0K
28.9K
Earning Date
12-05-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$136,846,182.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.45
50.00
52 Week Low
$0.56
$4.55
52 Week High
$2.03
$153.90

Technical Indicators

Market Signals
Indicator
BGI
ABP
Relative Strength Index (RSI) 36.09 55.92
Support Level $1.00 $5.55
Resistance Level $1.09 $6.38
Average True Range (ATR) 0.05 0.54
MACD -0.01 -0.26
Stochastic Oscillator 20.32 33.88

Price Performance

Historical Comparison
BGI
ABP

About BGI Birks Group Inc.

Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.

About ABP Abpro Holdings Inc

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: